Abstract: PO0192
AKI in COVID-19 Patients and History of Cancer: Role of D-Dimer as a Potential Risk Factor
Session Information
- AKI: Epidemiology, Risk Factors, and Prevention
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 101 AKI: Epidemiology, Risk Factors, and Prevention
Authors
- Gerardine, Supriya, Weill Cornell Medicine, New York, New York, United States
- Jaimes, Edgar A., Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Derkach, Andriy, Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Jaffer Sathick, Insara, Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Gutgarts, Victoria, Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Latcha, Sheron, Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Glezerman, Ilya, Memorial Sloan Kettering Cancer Center, New York, New York, United States
Background
New York City (NYC) was the epicenter of the coronavirus disease 19 (COVID-19) pandemic in the United States in the Spring of 2020. Complications of severe COVID-19 infection included ARDS, thrombotic events and acute kidney injury (AKI).
Patients with co-morbidities such as diabetes mellitus, heart failure, chronic kidney disease and cancer had higher mortality rates. The rate of AKI in NYC was between 37%-46% in hospitalized patients. In this study we determined the role of coagulation activation as assessed by D-Dimer as a risk factor for AKI in COVID-19 patients with history of cancer.
Methods
We used the MSKCC electronic medical records to obtain patient data. We included all patients above 18 years of age who were hospitalized at MSKCC for COVID-19 infection and had a confirmed positive RT-PCR nasopharyngeal swab test for SARs-CoV2 between March 1, 2020 to May 1, 2020. Patents with ESRD on dialysis were excluded.
Results
We had a total of 361 patients with COVID-19 infection who were hospitalized and of these 25.7% (93/361) required admission to the intensive care unit (ICU). AKI developed in 9% (33/361) of patients and of these 69% (23/33) developed AKI after ICU admission. 26 patients who developed AKI had D-dimer levels checked and 88.4% of these patients had an elevated D-dimer vs 34.5% (67/194) positivity rate for patients with no AKI (p= 1.4e-7). D-dimer and AKI association shown in Figure 1.
Conclusion
The rate of AKI in our population was significantly lower than in general population despite having history of active or treated cancer as a comorbidity. The majority of patients developed AKI after admission to the ICU. An elevated D-dimer was noted in 88.4% of patient who developed AKI and were tested for it. This could make D-Dimer a risk marker for AKI in cancer patients with COVID-19.